Building testing capacity for past and current SARS-CoV-2 infection in animals with potential exposure to humans with COVID-19

NIH RePORTER · FDA · U18 · $83,739 · view on reporter.nih.gov ↗

Abstract

Project Abstract The goal of this proposal is to build testing capacity at the Wisconsin Veterinary Diagnostic Laboratory (WVDL) to perform serology detection and whole genome sequencing of SARS- CoV-2 from animal samples. We are requesting funding for the purchase of reagents and equipment to validate the SARS-CoV-2 Surrogate Virus Neutralization Test kit (GenScript) as a multi-species diagnostic serology assay, with specific focus on the detection of antibodies against SARS-CoV-2 virus in companion animals. As part of a proposed Genomic Consortium, we are requesting funds to purchase a QIAxcel Adnavced System (Qiagen) and a MinION (Oxford Nanopore) Enhanced Pack to validate library preparation and sequencing kits for iSeq (Illumina) and MinION for targeted SARS-CoV-2 sequencing. We will participate in the development and validation of bioinformatics pipelines that will be made accessible to veterinary diagnostic personnel to quickly and efficiently determine genomic lineages, and develop a staff training and development program to maintain proficiency in sequencing and to analyze the SARS-COV-2 genome. Together, we aim to have a validated multi-species serological diagnostic assay and trained staff with streamline workflow for whole genome sequence of the SARS-CoV-2 virus detected in animal specimens, to increase our capacity and capability to support diagnostic activities for the ongoing global SARS-CoV-2 pandemic. In turn, the acquired equipment and training will help building WVDL’s readiness to response to potentially other important future veterinary disease outbreaks that are important to human food safety and animal welfare.

Key facts

NIH application ID
10449498
Project number
1U18FD007520-01
Recipient
UNIVERSITY OF WISCONSIN-MADISON
Principal Investigator
Ailam Lee Lim
Activity code
U18
Funding institute
FDA
Fiscal year
2021
Award amount
$83,739
Award type
1
Project period
2021-09-15 → 2022-09-30